Skip to main content

Displaying 241 - 260 of 1511

Otto Bock HealthCare North America, Inc., In the Matter of

The FTC issued an administrative complaint challenging the merger of two prosthetics manufacturers that are top sellers of prosthetic knees equipped with microprocessors. According to the FTC’s complaint, Otto Bock’s consummated acquisition of FIH Group Holdings (owner of Freedom Innovations) harmed competition in the U.S. market for microprocessor prosthetic knees by eliminating head-to-head competition between the two companies, removing a significant and disruptive competitor, and entrenching Otto Bock’s position as the dominant supplier. Microprocessor knees, which use microprocessors to adjust the stiffness and positioning of the joint in response to variations in walking rhythm and ground conditions, provide a stable platform for amputees. Compared to other products, microprocessor prosthetic knees reduce the risk of falling, cause less pain, and promote the health and function of the sound limb. In addition to issuing an administrative complaint, the Commission authorized agency staff to seek a temporary restraining order, preliminary injunction, and ancillary relief in federal court, should doing so be necessary to ensure the Freedom Innovations business remains viable and to preserve the Commission ability to order effective relief. On Dec. 1, 2020, the Commission announced approval for the divestiture of the Freedom assets.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
171 0231
Docket Number
9378
Case Status
Closed
Jul27

PrivacyCon 2021

The FTC hosted its sixth annual PrivacyCon on July 27, 2021. PrivacyCon 2021 brought together a diverse group of stakeholders, including researchers, academics, industry representatives, consumer...

Sunday Riley Modern Skincare, LLC; In the Matter of

On October 21, 2019, the FTC announced it had halted the deceptive online marketing tactics of cosmetics firm Sunday Riley Modern Skincare, LLC and its CEO. Under the order settling the FTC’s complaint the defendants were banned from misleading consumers by posting fake reviews of the company’s products on a major retailer’s website, at the CEO’s direction, and by failing to disclose that the reviewers were company employees. The FTC announced approval of the final order in November 2020.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
192 3008
Case Status
Pending

AbbVie Inc. and Allergan plc, In the Matter of

Pharmaceutical companies AbbVie Inc. and Allergan plc have agreed to divest assests to settle Federal Trade Commission charges that AbbVie's proposed $63 billion acquisition of Allergan would violate federal antitrust law. On Sept. 4, 2020, the Commission announced the final consent agreement in this matter.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
191 0169
Case Status
Pending